DAPASUG-M 5/500 TABS
MRP: 3
Packaging: 10x10
Pack Type: tablet
Composition:
Dapagliflozin 5mg+ metformin 500mg (extended release)
Indication:
used to improve blood sugar control in adults with type 2 diabetes mellitus, especially when diet, exercise, and single-agent therapy do not provide adequate glycemic control.
Description:
Dapagliflozin 5 mg + Metformin HCl 500 mg (ER) is an oral fixed-dose combination used in the treatment of Type 2 Diabetes Mellitus.
This dual-action formulation helps in improving glycemic control by targeting insulin resistance and glucose excretion mechanisms.
Dapagliflozin is an SGLT2 inhibitor that works by blocking glucose reabsorption in the kidneys, promoting urinary glucose excretion.
Metformin (ER) is a biguanide that reduces hepatic glucose production and increases insulin sensitivity.
Together, they offer complementary glycemic control and may support weight loss and blood pressure reduction.
Tags:
- Dual mechanism lowers both fasting and postprandial glucose
- Weight-neutral or weight-reducing
- Supports cardiovascular and renal protection (dapagliflozin)
- Extended-release Metformin improves tolerability and compliance
- Lower risk of hypoglycemia compared to sulfonylureas
Usage Information
Dosage
Recommended Dose: 1 tablet once or twice daily with meals (based on clinical need) Do not crush or chew the extended-release tablet Dosage may be adjusted by a physician based on glycemic response
Side Effects
Genital or urinary tract infections (from dapagliflozin) Mild nausea, bloating, or diarrhea (initially from metformin) Increased urination, dehydration risk Rare: Lactic acidosis (serious but rare with metformin)
Contraindications
Type 1 Diabetes Mellitus Severe renal impairment (eGFR < 30 mL/min/1.73m²) Ketoacidosis History of lactic acidosis Hypersensitivity to any component of the formulation Not recommended during pregnancy or breastfeeding